Therapy-related myelodysplastic syndrome/acute myeloid leukemia following fludarabine therapy for non-Hodgkin lymphoma and chronic lymphocytic leukemia in Thai patients

Leukemia and Lymphoma

Volumn 51, Issue 11, 2010, Pages 2120-2125

  Niparuck, Pimjai ^a   Kanoksil, Wasana ^a   Chuncharunee, Suporn ^a   Boonsakan, Paisarn ^a   Ungkanont, Artit ^a   Angchaisuksiri, Pantep ^a   Karntisaviwat, Kanlaya ^a   Apilugsanachit, Axara ^a   Rerkamnuatchoke, Budsaba ^a   Jootar, Saengsuree ^a   Nitiyanant, Prawat ^a   Atichartakarn, Vichai ^a  

^a MAHIDOL UNIVERSITY   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; IFOSFAMIDE; METHOTREXATE; METHYLPREDNISOLONE; RITUXIMAB; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ANEMIA; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER STAGING; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; DYSERYTHROPOIESIS; EOSINOPHILIA; FEMALE; FOLLICULAR LYMPHOMA; HAIRY CELL LEUKEMIA; HUMAN; LETTER; LYMPHOCYTOMA; MALE; MANTLE CELL LYMPHOMA; MARGINAL ZONE LYMPHOMA; MEAN CORPUSCULAR VOLUME; MYELODYSPLASTIC SYNDROME; NEUTROPENIA; NONHODGKIN LYMPHOMA; PANCYTOPENIA; PRIORITY JOURNAL; THAILAND; THROMBOCYTOPENIA; TREATMENT DURATION;

ADULT; AGED; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LEUKEMIA, MYELOID, ACUTE; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; NEOPLASMS, SECOND PRIMARY; PROGNOSIS; RETROSPECTIVE STUDIES; THAILAND; VIDARABINE; YOUNG ADULT;

EID: 78649266330     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2010.505675     Document Type: Letter

References (8)

1. Morrison VA, Rai KR, Peterson BL, et al. Therapyrelated myeloid leukemias are observed in patients with chronic lymphocytic leukemia after treatment with fludarabine and chlorambucil: results of an intergroup study, cancer and leukemia group B 9011. J Clin Oncol 2002;20:3878-3884.
2. Tam SC, Seymour FJ, Prince MH, et al. Treatment-related myelodysplasia following fludarabine combination chemotherapy. Hematologica 2006;91:1546-1550.
3. Yamauchi T, Nowak BJ, Keating MJ, Plunkett W. DNA repair initiated in chronic lymphocytic leukemia lymphocytes by 4-hydroperoxycyclophosphamide is inhibited by fludarabine and clofarabine. Clin Cancer Res 2001;7:3580-3589.
4. Di Gaetano N, Xiao Y, Erba E, et al. Synergism between fludarabine and rituximab revealed in a follicular lymphoma cell line resistant to the cytotoxic activity of either drug alone. Br J Haematol 2001;114:800-809.
5. Byrd JC, Peterson BL, Morrison VA, et al. Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712). Blood 2003;101:6-14.
6. Wierda W, O'Brien S, Wen S, et al. Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. J Clin Oncol 2005;23:4070-4078.
7. McLaughlin P, Estey E, Glassman A, et al. Myelodysplasia and acute myeloid leukemia following therapy for indolent lymphoma with fludarabine, mitoxantrone, and dexamethasone (FND) plus rituximab and interferon alpha. Blood 2005;105:4573-4575.
8. Misgeld E, Germing U, Aul C, Gattermann N. Secondary myelodysplastic syndrome after fludarabine therapy of a low-grade non-Hodgkin's lymphoma. Leuk Res 2001;25:95-98.